title: Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis.
abstract: A meta-analysis was conducted of individual patient data (n = 3292) from three randomized controlled trials of corifollitropin alfa versus rFSH: Engage (150 µg corifollitropin alfa n = 756; 200 IU rFSH n = 750), Ensure (100 µg corifollitropin alfa n = 268; 150 IU rFSH n = 128), and Pursue (150 µg corifollitropin alfa n = 694; 300 IU rFSH n = 696). Women with regular menstrual cycles aged 18-36 and body weight >60 kg (Engage) or ≤60 kg (Ensure), or women aged 35-42 years and body weight ≥50 kg (Pursue), received a single injection (100 µg or 150 µg) of corifollitropin alfa (based on body weight and age) or daily rFSH. The difference (corifollitropin alfa minus rFSH) in the number of oocytes retrieved was +1.0 (95% CI: 0.5-1.5); vital pregnancy rate: -2.2% (95% CI: -5.3%-0.9%); ongoing pregnancy rate: -1.7% (95% CI: -4.7%-1.4%); and live birth rate: -2.0% (95% CI: -5.0%-1.1%). The odds ratio for overall OHSS was 1.15 (95% CI: 0.82-1.61), and for moderate-to-severe OHSS: 1.29 (95% CI: 0.81-2.05). A single dose of corifollitropin alfa for the first 7 days of ovarian stimulation is a generally well-tolerated and similarly effective treatment compared with daily rFSH.
authors.affiliation: Department of Reproductive Medicine and Gynecological Endocrinology, University Clinic of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
authors.forename: Georg
authors.initials: G
authors.lastname: Griesinger
authors.affiliation: Huntington Reproductive Center, Encino, CA, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Boostanfar
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Keith
authors.initials: K
authors.lastname: Gordon
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Davis
authors.initials: D
authors.lastname: Gates
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Christine
authors.initials: C
authors.lastname: McCrary Sisk
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: bjstegmann@aol.com.
authors.forename: Barbara J
authors.initials: BJ
authors.lastname: Stegmann
mesh_terms: D000328:Adult; D001723:Birth Rate; D001835:Body Weight; D005260:Female; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use*; D043373:Follicle Stimulating Hormone, Human / Q000627:therapeutic use*; D006801:Humans; D016017:Odds Ratio; D009865:Oocytes / Q000166:cytology / Q000187:drug effects; D016471:Ovarian Hyperstimulation Syndrome; D010062:Ovulation Induction; D011247:Pregnancy; D018873:Pregnancy Rate; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use*
chemical_list: D043373:Follicle Stimulating Hormone, Human; D011994:Recombinant Proteins; C437186:follicle stimulating hormone, human, with HCG C-terminal peptide; D005640:Follicle Stimulating Hormone
keywords: GnRH antagonist; corifollitropin alfa; ovarian hyperstimulation syndrome; ovarian stimulation; pregnancy